WallStreetZenWallStreetZen

NASDAQ: LAB
Standard Biotools Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for LAB

Based on 1 analyst offering 12 month price targets for Standard Biotools Inc

Min Forecast
$1.35-10%
Avg Forecast
$1.35-10%
Max Forecast
$1.35-10%

Should I buy or sell LAB stock?

Based on 1 analyst offering ratings for Standard Biotools Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LAB's forecast from analysts indicates a "Hold", our proven Zen Rating quant model rates LAB as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their LAB stock forecasts and price targets.

LAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-05

1 of 1

Forecast return on equity

Is LAB forecast to generate an efficient return?

Company
N/A
Industry
11.76%
Market
230.3%

Forecast return on assets

Is LAB forecast to generate an efficient return on assets?

Company
N/A
Industry
14.44%

LAB earnings per share forecast

What is LAB's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.22
Avg 2 year Forecast
-$0.15
Avg 3 year Forecast
-$0.18

LAB revenue forecast

What is LAB's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$87.2M-32.29%
Avg 2 year Forecast
$80.5M-37.49%
Avg 3 year Forecast
$84.8M-34.19%
LAB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LAB revenue growth forecast

How is LAB forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
-13.81%
Industry
5.17%
Market
25.31%
LAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LAB vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
LAB$1.50$1.35-10.00%Hold
MYGN$7.63$8.00+4.85%Buy
ACRS$2.83$11.00+288.69%Strong Buy
FLGT$29.58$30.00+1.42%Buy
CDNA$17.87$21.67+21.25%Buy
View Top Diagnostic & Research Stocks

Standard Biotools Stock Forecast FAQ

Is Standard Biotools Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LAB) stock is to Hold LAB stock.

Out of 1 analyst, 0 (0%) are recommending LAB as a Strong Buy, 0 (0%) are recommending LAB as a Buy, 1 (100%) are recommending LAB as a Hold, 0 (0%) are recommending LAB as a Sell, and 0 (0%) are recommending LAB as a Strong Sell.

If you're new to stock investing, here's how to buy Standard Biotools stock.

What is LAB's earnings growth forecast for 2025-2027?

(NASDAQ: LAB) Standard Biotools's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 16.06%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.

Standard Biotools's earnings in 2025 is -$128,251,000.On average, 4 Wall Street analysts forecast LAB's earnings for 2025 to be -$85,450,435, with the lowest LAB earnings forecast at -$86,681,044, and the highest LAB earnings forecast at -$84,796,674. On average, 4 Wall Street analysts forecast LAB's earnings for 2026 to be -$58,261,660, with the lowest LAB earnings forecast at -$56,531,116, and the highest LAB earnings forecast at -$60,569,053.

In 2027, LAB is forecast to generate -$69,913,992 in earnings, with the lowest earnings forecast at -$67,837,339 and the highest earnings forecast at -$72,682,863.

What is LAB's revenue growth forecast for 2025-2027?

(NASDAQ: LAB) Standard Biotools's forecast annual revenue growth rate of -13.81% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.31%.

Standard Biotools's revenue in 2025 is $128,827,000.On average, 4 Wall Street analysts forecast LAB's revenue for 2025 to be $33,543,333,671, with the lowest LAB revenue forecast at $29,396,180,246, and the highest LAB revenue forecast at $40,533,194,636. On average, 4 Wall Street analysts forecast LAB's revenue for 2026 to be $30,968,283,659, with the lowest LAB revenue forecast at $29,659,992,120, and the highest LAB revenue forecast at $32,704,596,503.

In 2027, LAB is forecast to generate $32,605,763,191 in revenue, with the lowest revenue forecast at $31,280,550,775 and the highest revenue forecast at $34,279,391,873.

What is LAB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: LAB) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 14.44%.

What is LAB's Price Target?

According to 1 Wall Street analyst that have issued a 1 year LAB price target, the average LAB price target is $1.35, with the highest LAB stock price forecast at $1.35 and the lowest LAB stock price forecast at $1.35.

The Wall Street analyst predicted that Standard Biotools's share price could fall to $1.35 by Nov 5, 2026. The average Standard Biotools stock price prediction forecasts a potential downside of 10% from the current LAB share price of $1.50.

What is LAB's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: LAB) Standard Biotools's current Earnings Per Share (EPS) is -$0.33. On average, analysts forecast that LAB's EPS will be -$0.22 for 2025, with the lowest EPS forecast at -$0.23, and the highest EPS forecast at -$0.22. On average, analysts forecast that LAB's EPS will be -$0.15 for 2026, with the lowest EPS forecast at -$0.15, and the highest EPS forecast at -$0.16. In 2027, LAB's EPS is forecast to hit -$0.18 (min: -$0.18, max: -$0.19).

What is LAB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: LAB) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.